Sigachi Indust. Q1 FY27 Earnings Call — Analysis (NSE: SIGACHI)

Sigachi maintains FY27 revenue and margin guidance despite a subdued Q1, banking on second-half capacity ramp-up and product mix improvement.

20 Aug 2026 · Analysis by Alpha Inflection

Result quality: strong — Loss reversed. Management sentiment: optimistic.

The take

Q1FY27 Revenue ₹121.27 Cr ( flat QoQ ) . New guidance — FY27 fy27 consolidated revenue ₹650-675 Cr . New story: Capacity expansion as growth catalyst .

Results

Q1FY27 operating income ₹121.27 Cr flat QoQ; EBITDA margin 13.6%; net profit ₹8.14 Cr (PAT margin 6.76%). MCC realized at ₹241.36/kg, up from ₹216/kg in Q4.

Financial highlights

Guidance

FY27 revenue guidance of ₹650-675 Cr and full-year EBITDA margin of 18% reiterated, with quarter-on-quarter improvements expected from Q2.

What management committed to

• [Sigachi Industries] consolidated revenue in FY27 will be ₹650-675 Cr. — ₹650-675 Cr, FY27
• FY27 full-year EBITDA margin will be 18%. — 18%, FY27
• [Sigachi's] API business revenue will exceed ₹100 Cr in FY27. — >₹100 Cr, FY27
• The 12,000 MTPA MCC capacity expansion at [Dahej-2] will be commissioned by Q2FY28. — 12,000 MTPA, Q2FY28
• The CCS (Croscarmellose Sodium) facility at [Dahej SEZ] will become operational in FY28. — FY28
• Insurance claim for [Hyderabad facility incident] will be settled by September 2026 (full amount with discount or ad-hoc). — Q2FY27
• Capex spending in FY27 will exceed ₹100 Cr. — >₹100 Cr, FY27
• FY28 capex will be in the range of ₹150-200 Cr. — ₹150-200 Cr, FY28
• Receivables days will be reduced to around 90 by end of FY27. — ~90 days, FY27
• Revenue and EBITDA margin will improve quarter-on-quarter for each of the remaining three quarters of FY27. — remaining three quarters of FY27

Key themes

Capacity recovery and product mix enhancement

How the narrative shifted

• Capacity expansion as growth catalyst: Management frames the Dahej-2 MCC and CCS projects as the primary means to regain lost market share and capture export demand, emphasizing that demand will absorb the new capacity quickly given 30-year customer relationships.
• Product mix migration to higher-value excipients: The launch of co-processed excipients like HiCel SMCC Nutra and shift to high-margin API molecules are positioned as key levers to lift overall margins above historical MCC levels, with CCS margins projected above 25%.
• Recovery from capacity loss and customer regain: The loss of 6,000 MTPA at Hyderabad forced customers to alternate suppliers; management is confident that once capacity returns, those customers will come back due to deep relationships and quality reputation.
• Regulatory quality as competitive barrier: Management argues that MCC is not a commodity; regulatory approvals, quality consistency, and customer validation create high entry barriers, protecting Sigachi's market position against new capacity additions.
• Export-led demand and distributor channel: Exports account for over 53% of production; CCS facility is already receiving inquiries from international customers, reinforcing the global demand pull and the goodwill built over decades.

Operational commentary

• Dahej-2 12,000 MTPA MCC expansion now targeted for commissioning by Q2FY28, delayed from earlier Q1FY28 timeline.
• Croscarmellose Sodium (CCS) 1,800-ton facility at Dahej SEZ on track for FY28 commercial operations; already receiving export customer inquiries.
• Launched HiCel SMCC Nutra, a co-processed excipient combining MCC and magnesium aluminometasilicate, targeting nutraceutical formulation challenges – advancing value-chain differentiation.
• API business expanding with new high-margin molecules (Sparsentan, Bempedoic acid); revenue run-rate expected to accelerate, supporting CEP filings for regulated markets.
• Export volumes remain dominant (53.5% of MCC production), with demand driven by long-standing supply relationships across 65 countries.
• Insurance claim for Hyderabad incident: assessment completed, e-auction concluded; management expects settlement by September 2026 (full claim with discount or ad-hoc payment).
• Working capital: trade receivables at 93-94 days, target reduction to ~90 days by FY27-end and eventually to 75-80 days.

Analyst Q&A

• Q. What is the demand and pricing scenario in MCC, and are we worried about oversupply as Indian players expand?

  Management explained that capacity alone is not enough; regulatory compliance, quality approval from regulated customers, and long-standing relationships matter. They cited Asia Pacific growth at 7-8% CAGR and a $1.4 bn market by 2035.

• Q. How will margins reach 18% for the full year given Q1 at 13.6%?

  Fixed costs remain constant while revenues ramp up quarter-on-quarter; mix improvement and debottlenecking will drive margins.

• Q. Will the promoter buy shares from the open market after warrant forfeiture?

  "If anything is there, we'll make an announcement, sir."

• Q. Reconciliation of annual revenue guidance of ₹650-675 Cr with current capacity and utilization.

  CFO gave a rough calculation (19,600 MT capacity × ₹241 realization) and mentioned API+O&M contribution of ~₹200 Cr, saying "you please recalculate" without a clear quarterly bridge.

View source

Research and educational content only. Not investment advice.